cyclopentancarboxylic acid (3-imidazo[1,2-a]pyrimidin-2-ylphenyl)amide | 863020-05-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: cyclopentancarboxylic acid (3-imidazo[1,2-a]pyrimidin-2-ylphenyl)amide
• 英文别名: N-(3-imidazo[1,2-a]pyrimidin-2-ylphenyl)cyclopentanecarboxamide
• CAS: 863020-05-7
• 化学式: C₁₈H₁₈N₄O
• 分子量: 306.367
• InChiKey: CNUHVAISLIVBJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  59.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM
  申请人：Ivaschenko Andrey Alexandrovich

  公开号：US20110053915A1

  公开（公告）日：2011-03-03

  The invention relates to novel heterocyclic compounds and to the use thereof, to pharmaceutical compositions containing said chemical compounds as an active ingredient and to the use thereof for producing medicinal preparations for the human being and warm-blood animals for treating diseases caused by the aberrant activity of an Hedgehog (Hh)-signal system, in particular oncological diseases. The invention also relates to the use of the above-mentioned compounds in the form of ‘molecular pharmacological tools’ for examining (in vitro and in vivo) the biochemical features of the Hh-signal system, in particular, the interaction of Hh protein and transmembrane proteins, namely, suppressor Patched (Ptc) and protooncogenic proteins. The eight groups of the claimed compounds comprise the derivatives of 2,6-dihydro-7H-pyrazolo[3,4-d]pyridazine-7-one and 1,4-dihydropyrazolo[3,4-b][1,4]thiazine-5-one; N-acidylated 4-imidazo[1,2-a]pyrimidine-2-il-anilines; ([4H-thino[3,2-b]pyrrol-5-il) carbonyl]piperidine-4-carbonic acid amides; 2-(4carbomoilpyperidine-1-il)-isonicotinic acid amides; N-sylphonyl-1,2,3,4-tetrahydroquinoline-6-carbonic acid amides; and pyridine 2-amino-4,5,6,7-tetrahydrothieno[2,3-c] N-acidylated 3-azole derivatives.

  该发明涉及新颖的杂环化合物及其用途，包括含有该化合物作为活性成分的药物组合物，以及用于制备用于治疗由Hedgehog（Hh）信号系统异常活性引起的人类和温血动物疾病的药物制剂。该发明还涉及上述化合物的使用形式为“分子药理学工具”，用于检查Hh信号系统的生化特征（体外和体内），特别是Hh蛋白与跨膜蛋白之间的相互作用，即抑制剂Patched（Ptc）和原癌基因蛋白。所述化合物的八个类别包括2,6-二氢-7H-吡唑并[3,4-d]吡啶嗪-7-酮和1,4-二氢吡唑并[3,4-b][1,4]噻嗪-5-酮的衍生物；N-酰化的4-咪唑并[1,2-a]嘧啶-2-基-苯胺；([4H-噻吩[3,2-b]吡咯-5-基)羰基]哌啶-4-羧酸酰胺；2-(4-羧甲基哌啶-1-基)-异尼古丁酸酰胺；N-磺酰基-1,2,3,4-四氢喹啉-6-羧酸酰胺；以及吡啶2-氨基-4,5,6,7-四氢噻吩[2,3-c] N-酰化的3-唑衍生物。
• Novel therapeutic target for protozoal diseases
  申请人：Rathore Dharmender

  公开号：US20070148185A1

  公开（公告）日：2007-06-28

  A novel Hemozoin Detoxification Protein (HDP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. HDP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, HDP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on HDP, or antigenic epitopes of HDP, either alone or in combination with other parasite antigens. Methods for the development and use of compounds that inhibit the catalytic activity of HDP, and diagnostic and laboratory methods utilizing HDP are also provided. HDP is also referred to herein as Fasciclin Related Adhesive Protein (FRAP).
• US8486945B2
  申请人：——

  公开号：US8486945B2

  公开（公告）日：2013-07-16
• [EN] A NOVEL THERAPEUTIC TARGET FOR PROTOZOAL DISEASES<br/>[FR] UNE NOUVELLE CIBLE THÉRAPEUTIQUE POUR LES MALADIES À PROTOZOAIRE
  申请人：VIRGINIA TECH INTELL PROP

  公开号：WO2007047579A2

  公开（公告）日：2007-04-26

  [EN] A novel Hemozoin Detoxification Protein (HDP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. HDP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, HDP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on HDP, or antigenic epitopes of HDP, either alone or in combination with other parasite antigens. Methods for the development and use of compounds that inhibit .the catalytic activity of HDP, and diagnostic and laboratory methods utilizing HDP are also provided. HDP is also referred to herein as Fasciclin Related Adhesive Protein (FRAP).
  [FR] L'invention concerne une nouvelle protéine de désintoxication de l'hémozoïne (PDH) de plasmodium et de parasites apparentés, comme cible pour intervention thérapeutique dans des maladies causées par lesdits parasites. La PDH s'est avéré jouer un rôle critique dans l'adhésion à des, ou l'invasion de, cellules hôtes par le parasite. En outre, La PDH catalyse la neutralisation de l'hème par le parasite, en encourageant sa polymérisation en hémozoïne. La présente invention concerne des méthodes et des compositions pour des thérapies basées sur l'administration de vaccins à base de protéine, d'ADN ou de cellules, et/ou d'anticorps basés sur la PDH ou d'épitopes antigènes de la PDH, seuls ou en combinaison avec d'autres antigènes de parasites. L'invention concerne aussi des méthodes pour développer et utiliser des composés qui inhibent l'activité catalytique de la PDH, et des méthodes diagnostiques et de laboratoire utilisant la PDH. On fait également référence ici à la PDH comme protéine adhésive apparentée à la fascicline (FRAP : Fasciclin Related Adhesive Protein).
• [EN] HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES D'UNE CASCADE DE SIGNAUX Hh, COMPOSITIONS MÉDICINALES À BASE DE CES INHIBITEURS ET MÉTHODES DE TRAITEMENT DE MALADIES PROVOQUÉES PAR L'ACTIVITÉ ABERRANTE DU SYSTÈME DE SIGNALISATION Hh
  申请人：ALLA CHEM LLC

  公开号：WO2009077956A2

  公开（公告）日：2009-06-25

  Настоящее изобретение относится к новым гетероциклическим соединениям и их применению, а также к фармацевтическим композициям, включающим данные химические соединения в качестве активного ингредиента, и использованию их при изготовлении лекарственных препаратов для людей и теплокровных животных, применяемых для лечения болезней, связанных с абберантной активностью Неdgеhоg (Hh) сигнальной системы, в частности, онкологических заболеваний. Изобретение относится также к применению данных соединений в качестве «мoлeкyляpныx фармакологических инструментов) для исследований (in vitrо и in vivо) биохимических особенностей Hh сигнальной системы, в частности, взаимодействия Hh протеина и трансмембранных белков: супрессорного Раtсhеd (Рtс) и протоонкогенного Smооthеnеd (Smо). Восемь групп заявляемых соединений включают в себя производные 2,6-дигидpo- 7H-пиpaзoлo[3,4-d]пиpидaзин-7-oнa и 1,4-дигидpoпиpaзoлo[3,4-b][1,4]тиaзин-5-oнa; N- ацилированные 4-имидaзo[l,2-a]пиpидин-2-ил- и 4-имидaзo[l,2-a]пиpимидин-2-ил- анилины; амиды [(4H-тиeнo[3,2-b]пиppoл-5-ил)кapбoнил]пипepидин-4-кapбo новой кислоты; амиды 2- (4-кapбaмoилпипepидин-1-ил)-изo никотиновой кислоты; амиды N- cyльфoнил-1,2,3,4-тeтpaгидpoxинoлин-6-кapбoнoвoй кислоты; а также N-ацилированные 3-aзoлильныe производные 2-aминo-4,5,6,7-тeтpaгидpoтиeнo[2,3-c]пиpидинa.